GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vivoryon Therapeutics VVY.AS · EUR

Health Care · Euronext Amsterdam · 🇳🇱 Netherlands

Compare

0.66

+6.15%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−€8.9m

FY2016FY2025

Free cash flow

−€8.5m

FY2016FY2025

Shareholders' equity

€4.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue———€10.8m—————
Gross profit−€147,000−€147,000−€161,000€9.0m−€146,000−€88,000−€23,000−€106,000−€97,000
Research and development€4.4m€14.1m€20.2m€17.5m€13.2m€4.8m€4.8m€7.5m€11.0m
Operating income−€9.2m−€21.0m−€29.1m−€12.8m−€16.0m−€7.7m−€7.7m−€10.0m−€13.8m
Net income−€8.9m−€20.6m−€28.2m−€12.7m−€16.5m−€7.8m−€7.7m−€8.0m−€13.9m
Diluted earnings per share-0.31-0.79-1.23-0.63-0.83-0.52-0.94-0.97-1.79

Balance sheet

At each fiscal year end

FY2025FY2024FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets€7.5m€11.3m€31.4m€24.5m€29.8m€45.9m€4,048€10,762€22,366
Cash and short-term investments€5.6m€9.4m€26.6m€14.7m€26.3m€41.5m€3,783€10,291€21,897
Total liabilities€2.8m€3.4m€4.9m€8.0m€3.5m€3.2m€2,818€1,839€5,990
Debt€108,000€102,000€132,000€224,000€314,000€406,000€83,000——
Shareholders' equity€4.7m€7.9m€26.5m€16.6m€26.2m€42.7m€1,230€8,923€16,376
Shares outstanding29m26m23m20m20m15m8m8m8m

Cash flow

Fiscal years

FY2025FY2024FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−€8.5m−€19.2m−€21.8m−€11.3m−€14.0m−€11.6m−€6,994−€12,117−€13,255
Capital spending−€6,000−€2,000−€13,000−€28,000−€640,000−€47,000−€16−€7−€7
Free cash flow−€8.5m−€19.2m−€21.8m−€11.3m−€14.7m−€11.7m−€7,010−€12,124−€13,262

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
Revenue—————−€3.6m——
Gross profit−€67,000−€74,000−€73,000−€74,000−€73,000−€4.1m−€79,000−€80,000
Operating income−€3.4m−€3.7m−€5.5m−€7.2m−€13.8m−€18.1m−€10.7m−€15.8m
Net income−€3.4m−€3.4m−€5.5m−€7.0m−€13.6m−€17.6m−€10.7m−€15.6m
Diluted earnings per share-0.11-0.12-0.19-0.27-0.52-0.72-0.44-0.68
Cash from operations−€3.0m−€3.0m−€4.0m−€5.0m−€13.0m−€1.0m−€20.0m−€11.0m
Total assets€4.2m€7.5m€6.4m€11.3m€17.0m€30.8m€45.4m€31.4m
Cash and short-term investments€2.4m€5.6m€4.8m€9.4m€15.3m€28.6m€38.6m€26.6m
Debt€65,000€64,000€61,000€60,000€20,000€76,000€75,000€94,000
Shareholders' equity€1.6m€4.7m€3.2m€7.9m€14.0m€26.3m€41.5m€26.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-32.0%-10.5%-3.7%
Net income-32.0%-11.7%-4.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-4.6-2.5-7.0-8.4-30.1-10.9-10.4-2.7-10.7-9.9
Price to sales——-55.1—35.4—————

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.